Day One Biopharmaceuticals Inc (DAWN) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Day One Biopharmaceuticals Inc   (NASDAQ: DAWN)


Day One Biopharmaceuticals Inc's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Day One Biopharmaceuticals Inc's ROI in the fourth quarter of 2025?
Day One Biopharmaceuticals Inc recorded a cumulative net loss of $-193 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on investment (ROI) of -41.61%.

Within the Healthcare sector 177 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Dec 31 2025 quarter, so far to 1982, from total ROI ranking in the third quarter of 2025 at 3223.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Investment Change TTM 11.05 % 27.12 % 51.12 % 27.71 % 14.4 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 447 457 468 486 509
Return On Investment (TTM) -41.61 % -52.24 % -27.31 % -16.99 % -16.62 %
DAWN's Overall Ranking # 1982 # 3223 # 2807 # 2509 # 0
Seq. Investment Change TTM -3.23 % -5.12 % 8.64 % 11.33 % 10.77 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -193 -251 -138 -79 -70

DAWN Company Profile >> Back to DAWN Roi Comparisons >> See Annual DAWN Return On Investment



Return On Investment DAWN's Ranking
Within: No.
Industry # 61
Sector # 178
Overall # 1982

Return On Investment Statistics
High Average Low
0.43 %
-24.55 %
-52.24 %
(Dec 31 2025)   (Sep 30 2025)



  News about Day One Biopharmaceuticals Inc Return on Investment ROI

Day One Biopharmaceuticals Secures Oversubscribed $175 Million Private Placement, While Maintaining Highest ROI Ranking in Healthcare Sector

July 30, 2024


BRISBANE, Calif., July 30, 2024 - Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) has made significant strides in securing funding for its mission of developing and commercializing targeted therapies for individuals with life-threatening diseases. The commercial-stage biopharmaceutical company recently announced an oversubscribed private placement of its securities, raising approximately $175.0 million in gross proceeds. This achievement comes as a positive development for Day One, especially considering its previous net loss of $-40 million during the 12 months ending in the third quarter of 2023.
The success of Day One s private placement demonstrates the confidence investors have in the company s prospects. Despite the significant losses reported last year, Day One Biopharmaceuticals managed to attract a favorable response from investors, leading to an oversubscribed funding round. While the private placement s proceeds amount to $175.0 million, it is important to note that these figures are before factoring in placement agent fees and other expenses.





Financial Statements
Day One Biopharmaceuticals Inc's IV. Quarter Investments $ 447 Millions DAWN's Balance sheet
Day One Biopharmaceuticals Inc's IV. Quarter Income $ -21 Millions Quarterly DAWN's Income Statement
DAWN's Income by Division See DAWN's Income by Division


DAWN Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 447 509 347 332 281
Y / Y Investment Growth -12.18 % 46.98 % 4.24 % 18.24 % -
Net Income in Millions 2 -7 -189 -142 -73
Y / Y Net Income Growth - - - - -
Annual Return On Investment 0.44 % -1.4 % -54.52 % -42.77 % -25.88 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 0.44 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
DAWN's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for DAWN's Competitors
Subscribers only: Roi for Day One Biopharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for DAWN's Customers

Other Ratios
DAWN's Roa DAWN's Inventory Turnover Ratio DAWN's Growth Rates DAWN's Dividend Statistics
DAWN's Profitability Ratios DAWN's Asset Turnover Ratio DAWN's Dividend Growth
DAWN's Roe DAWN's Valuation Ratios DAWN's Financial Strength Ratios DAWN's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.